<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">VALRUBICIN</span><br/>(val-roo'bi-sin)<br/><span class="topboxtradename">Valstar<br/></span><b>Classifications:</b> <span class="classification">antineoplastic</span>; <span class="classification">antibiotic</span><br/><b>Prototype: </b>Doxorubicin Hydrochloride<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>200 mg/5 mL vials</p>
<h1><a name="action">Actions</a></h1>
<p>Semisynthetic analog of doxorubicin. It is a cytotoxic antibiotic agent that inhibits the incorporation of nucleosides in
         DNA and RNA, which results in extensive chromosomal damage. Valrubicin interferes with DNA topoisomerase II, which is responsible
         for the normal DNA separation of strands and the resealing of DNA strands.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Valrubicin has higher antitumor efficacy and lower toxicity than doxirubicin.</p>
<h1><a name="uses">Uses</a></h1>
<p>Intravesical therapy of BCG-refractory carcinoma <i>in situ</i> of the urinary bladder.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to valrubicin, doxirubicin; patients with a perforated bladder, concurrent UTI, active infection; severe
         irritable bladder symptoms; severe myelosuppression; pregnancy (category C); lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Within 2 wk of a transureteral resection; compromised bladder mucosa; mild-to-moderate myelosuppression; concurrent use of
         anticoagulants, or history of bleeding disorders; GI disorders, renal impairment.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">BCG-Refractory Bladder Carcinoma <i>in situ</i> </span><br/><span class="rdage">Adult:</span> <span class="rdroute">Intravesically</span> 800 mg once per wk <small>x</small> 6 wk.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Instillation</span><ul>
<li>Avoid skin reactions by using gloves during preparation/administration.</li>
<li>Use only glass, polypropylene, or polyolefin containers and tubing.</li>
</ul>
<p><span class="routemethod">PREPARE:</span> Slowly warm 4 vials (5 mL each) to room temperature. When a precipitate is initially present, warm vials in hands until solution
                  clears. Add contents of 4 vials to 55 mL of 0.9% NaCl injection to yield 75 mL of diluted solution.  
               </p>
<p><span class="routemethod">INSTILL:</span> Aseptically insert a urethral catheter and drain the bladder. Use gravity drainage to instill valrubicin slowly over several
                  min. Withdraw catheter; instruct patient not to void for 2 h. Note: Do not leave a clamped catheter in place.  
               </p>
<ul>
<li>Refrigerate. Do not freeze.</li>
</ul>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Abdominal pain, asthenia, back pain, fever, headache, malaise, myalgia. <span class="typehead">CNS:</span> Dizziness. <span class="typehead">CV:</span> Vasodilation. <span class="typehead">GI:</span> Diarrhea, flatulence, nausea, vomiting. <span class="typehead">Urogenital:</span> <span class="speceff-common">Urinary frequency, urgency, dysuria, bladder spasm, hematuria, bladder pain, incontinence, cystitis, UTI,</span> nocturia, local burning, urethral pain, pelvic pain, gross hematuria, urinary retention. <span class="typehead">Respiratory:</span> Pneumonia. <span class="typehead">Skin:</span> Rash. <span class="typehead">Other:</span> Anemia, hyperglycemia, peripheral edema. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Not absorbed from bladder. <span class="typehead">Distribution:</span> Penetrates bladder wall. <span class="typehead">Metabolism:</span> Not metabolized. <span class="typehead">Elimination:</span> Almost completely excreted by voiding the instillate. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Therapeutic effectiveness: Indicated by regression of the bladder tumor.</li>
<li>Notify physician if bladder spasms with spontaneous discharge of valrubicin occur during/shortly after instillation.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Expect red-tinged urine during the first 24 h after administration.</li>
<li>Report prolonged passage of red-colored urine or prolonged bladder irritation.</li>
<li>Drink plenty of fluids during 48 h period following administration.</li>
<li>Use reliable contraception during therapy period (approximately 6 wk).</li>
<li>Do not breast feed infants during therapy period (approximately 6 wk).</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>